Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study

By afschroeder • October 8, 2025

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Heinemann V, Cremolini C, Randolph Hecht J, Schmoll HJ, Nakayama G, Lenz HJ, Andre T, Shi Q, de Gramont A, Shitara K, Yoshino T. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. Eur J Cancer. 2025 Oct 2;230:116034. doi: 10.1016/j.ejca.2025.116034. Epub ahead of print. PMID: 41056789.

Tags: Aide et Recherche en Cancérologie Digestive, Anti-epidermal growth factor receptor antibody, Bevacizumab, Clinical outcome, Hematology/Oncology, Metastatic colorectal cancer, Oxaliplatin-based doublet chemotherapy, Publications

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies

Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, Alexander E, Xie J, Gao[...]

Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on[...]

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or[...]